ライフサイエンスコーパス: pectoris

1 rction; 90 patients [42.1%], unstable angina pectoris).

2 coronary syndrome (82 MI, 44 unstable angina pectoris).

3 een patients with unstable and stable angina pectoris.

4 ith new-onset chest pain or worsening angina pectoris.

5 ith new-onset chest pain or worsening angina pectoris.

6 pectoris in most patients with stable angina pectoris.

7 ith ischemic heart disease and stable angina pectoris.

8 erse outcomes in patients with stable angina pectoris.

9 ms and myocardial perfusion in stable angina pectoris.

10 ndovascular approach in the relief of angina pectoris.

11 r combined CHD death/nonfatal MI plus angina pectoris.

12 cases of fatal CHD; and 124 cases of angina pectoris.

13 ocardial infarction (MI) and unstable angina pectoris.

14 e reserve in patients with refractory angina pectoris.

15 9%) men and 41 (5.2%) women developed angina pectoris.

16 ge less than the duration of unstable angina pectoris.

17 develop in association with unstable angina pectoris.

18 firmed acute myocardial infarction or angina pectoris.

19 ed incident coronary events including angina pectoris.

20 roses in other patients with unstable angina pectoris.

21 e clinical manifestations of unstable angina pectoris.

22 ignificance in patients with unstable angina pectoris.

23 0 cases of fatal CHD, and 60 cases of angina pectoris.

24 e procedure-related complications and angina pectoris.

25 symptoms in patients with refractory angina pectoris.

26 ith sympathetic phenotypes, including angina pectoris.

27 ciation exists between edentulism and angina pectoris.

28 nd 673,810 (2.3%) were diagnosed with angina pectoris.

29 ical outcomes in patients with stable angina pectoris.

30 ere more likely to be associated with angina pectoris.

31 4 cases of fatal CHD, and 68 cases of angina pectoris.

32 ith myocardial infarction or unstable angina pectoris.

33 atment for ischaemia in patients with angina pectoris.

34 nction, congestive heart failure, and angina pectoris.

35 ostic benefit in patients with stable angina pectoris.

36 d for the treatment of chronic stable angina pectoris.

37 chronic heart failure, and in stable angina pectoris.

38 approach to the treatment of chronic angina pectoris.

39 er acute coronary syndromes or stable angina pectoris.

40 in patients undergoing PCI for stable angina pectoris.

41 ssion in patients with chronic stable angina pectoris.

42 -term outcome in patients with stable angina pectoris.

43 or patients with chronic, symptomatic angina pectoris.

44 rapeutic approach to the treatment of angina pectoris.

45 ns exist for patients with refractory angina pectoris.

46 d to be normal and those with typical angina pectoris.

47 ailure (0.635 [95% CI, 0.615-0.655]), angina pectoris (0.649 [95% CI, 0.630-0.667]), and ischemic str

48 ease, 0.45% (95% CI: 0.13%, 0.77%) in angina pectoris, 0.75% (95% CI: 0.38%, 1.13%) in acute myocardi

49 ($20 764 [95% CI, $17 500-$24 027]), angina pectoris ($18 428 [95% CI, $16 102-$20 754]), and ischem

50 5%, a prior myocardial infarction; 5% angina pectoris; 2.3%, intermittent claudication; and 7%, a car

51 Angina pectoris affects at least 6.6 million people in the US a

52 ted the efficacy of TMR for relieving angina pectoris, although no study to date has specifically add

53 A total of 95 patients with angina pectoris and angiographically documented coronary artery

54 ily for treatment of hypertension and angina pectoris and are thought to act as allosteric modulators

55 pective trial patients with suspected angina pectoris and at least one cardiovascular risk factor wer

56 in subjects with personal history of angina pectoris and familial aneurysm.

57 Secondary endpoints were angina pectoris and hospitalization for heart failure.

58 d significantly activated in unstable angina pectoris and is not affected by severity of CAD or medic

59 Male patients (n = 328) with stable angina pectoris and ischemia on treadmill testing were randomly

60 erate drinking decreases the risk for angina pectoris and myocardial infarction in apparently healthy

61 tion, 10 angina pectoris, and 12 both angina pectoris and myocardial infarction) after the diagnosis

62 y atherosclerotic lesions, leading to angina pectoris and myocardial infarction, damages the heart, r

63 onary heart disease, including stable angina pectoris and the acute coronary syndromes.

64 opulation of patients with refractory angina pectoris and to present the therapeutic options currentl

65 dentified 80 conventional (eg, stable angina pectoris and type 2 diabetes) and unconventional (eg, di

66 events (11 myocardial infarction, 10 angina pectoris, and 12 both angina pectoris and myocardial inf

67 tients with recurrent or deteriorated angina pectoris, and 99 (95% confidence interval 69 to 129) uns

68 s of hypertension, diabetes mellitus, angina pectoris, and atrial fibrillation provides even more int

69 ar disorders, including hypertension, angina pectoris, and cardiac arrhythmia.

70 rdial infarction, functional class of angina pectoris, and hospitalizations for unstable angina.

71 nonfatal acute myocardial infarction, angina pectoris, and ischemic heart failure.

72 heart failure, cardiac dysrhythmias, angina pectoris, and peripheral artery disease), sociodemograph

73 oronary revascularization procedures, angina pectoris, and sudden CHD deaths.

74 of patients (94%) had class III or IV angina pectoris, and two patients (6%) had unstable symptoms pr

75 with stable angina pectoris, unstable angina pectoris,and ST-segment elevation myocardial infarction.

76 se (CHD); myocardial infarction (MI); angina pectoris; and performance of coronary bypass or angiopla

77 eserved ejection fraction (HFpEF) and angina pectoris (AP).

78 Although angina pectoris appears to be related statistically to subnorma

79 After we excluded isolated angina pectoris as an initial event, the lifetime risk of coron

80 Cardiac amyloidosis can present as angina pectoris associated with coronary flow reserve abnormali

81 pendent proportional hazards methods; angina pectoris at 5 years was modeled using univariate and mul

82 of nonfatal myocardial infarction and angina pectoris at 5 years, even after consideration of powerfu

83 noprost was linked to conditions like angina pectoris, atrial tachycardia and Meniere's disease, bima

84 of nitroglycerin in the treatment of angina pectoris began not long after its original synthesis in

85 ts in 60-90% of diseases that include angina pectoris, bronchial asthma, herpes simplex, and duodenal

86 Non-cardiac chest pain mimics angina pectoris but generally originates from the oesophagus.

87 antagonists are widely prescribed for angina pectoris but their effect on clinical outcome is controv

88 tory ischemia in patients with stable angina pectoris, but it remains to be established whether suppr

89 Patients with moderate/severe angina pectoris (Canadian Cardiovascular Society class 2-4) due

90 ascular event (myocardial infarction, angina pectoris, cerebrovascular accidents, or major coronary s

91 ian Cardiovascular Society grading of angina pectoris class 1 (n=1107, 18 events).

92 ian Cardiovascular Society grading of angina pectoris class 2 or higher (n=839, 34 events), increased

93 ian Cardiovascular Society grading of angina pectoris class interaction was observed in SCD risk (P=0

94 ian Cardiovascular Society grading of angina pectoris class, and exercise capacity were used as covar

95 ew episodes of myocardial infarction, angina pectoris, congestive heart failure, or stroke.

96 ction, CHD death, angiogram-confirmed angina pectoris, coronary artery bypass graft surgery, stents,

97 time risks of coronary heart disease (angina pectoris, coronary insufficiency, myocardial infarction,

98 n medical therapy for men with stable angina pectoris due to single-vessel disease.

99 Twenty developed angina pectoris during pacing, while 21 did not.

100 Angina pectoris during RCA occlusion tended to occur in fewer p

101 oronary ECG ST-segment elevation, and angina pectoris during the same 1-minute coronary occlusion.

102 d duration of clinical improvement in angina pectoris following TMR.

103 se tolerance test, and stable chronic angina pectoris (for at least 2 months) were recruited into a d

104 In patients with suspected stable angina pectoris, global longitudinal peak systolic strain asses

105 Patients with MI and unstable angina pectoris had higher VEGF levels compared with stable ang

106 k Heart Association class or comorbid angina pectoris, had lower activity levels, lived in Eastern Eu

107 Postprandial angina pectoris has been recognized for more than two centuries

108 ine GITS to conventional treatment of angina pectoris has no effect on major cardiovascular event-fre

109 coronary vein grafts and uncontrolled angina pectoris have limited options for therapy.

110 sk for ACS in individuals with stable angina pectoris (hazard ratio, 1.163 [95% CI, 1.082-1.251]) com

111 pared with individuals without stable angina pectoris (hazard ratio, 1.531 [95% CI, 1.497-1.565]).

112 y heart disease/heart failure, angina/angina pectoris, heart attack, and stroke, who provided complet

113 r and cerebrovascular diseases (e.g., angina pectoris, heart failure, cerebral infarction).

114 evascularization, hospitalization for angina pectoris, hospitalization for congestive heart failure,

115 ality, myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD, or do

116 used extensively in the treatment of angina pectoris, hypertension, and arrhythmia.

117 The indication for PTCA was stable angina pectoris in 69 patients, unstable angina in 22 and acute

118 The standard liquid meal precipitated angina pectoris in all patients.

119 of association between edentulism and angina pectoris in Mexican adults aged 35 years and older.

120 sponsible for myocardial ischemia and angina pectoris in most patients with stable angina pectoris.

121 The standard liquid meal induced angina pectoris in patients with coronary artery disease.

122 TMR improved the functional class of angina pectoris in patients with end stage coronary artery dise

123 h or without FFR guidance) for stable angina pectoris in Sweden between January 2005 and March 2016.

124 Stable angina pectoris in women has often been considered a "soft" dia

125 lar events (myocardial infarction and angina pectoris) in 498 women with systemic lupus erythematosus

126 D progression in patients with stable angina pectoris is associated with increased C-reactive protein

127 Angina pectoris is associated with morbidity and mortality.

128 Refractory angina pectoris is defined, and traditional medical therapies a

129 to the risk for other events, such as angina pectoris, is not known.

130 50 diseases monitored, a single one, angina pectoris, is significantly elevated (3.3x) in iciHHV-6+

131 tiple pathobiological precipitants of angina pectoris, ischaemia and infarction.

132 tiple pathobiological precipitants of angina pectoris, ischemia, and infarction.

133 n network meta-analyses of stroke and angina pectoris, limiting the conclusiveness of findings for th

134 Angina pectoris may arise from obstructive coronary artery dise

135 ] for every 0.26 mmol/L increase) and angina pectoris (multivariate odds ratio, 1.049 [95% confidence

136 focal microscope x z - scanning of cutaneous pectoris muscle fibres varied linearly with [1/extracell

137 the neuromuscular junction of frog cutaneous pectoris muscle.

138 to assess risk for a first CHD event (angina pectoris, myocardial infarction, or cardiac death) alone

139 7.9 years, 76 subjects developed CEs (angina pectoris, myocardial infarction, or coronary death).

140 5 subjects developed coronary events (angina pectoris, myocardial infarction, or coronary death): 21

141 tion (n=5371, 901 deaths), and stable angina pectoris (n=6536, 965 deaths) in 4 age categories.

142 otide and neurotransmitter in frog cutaneous pectoris nerve-muscle preparations.

143 ents with clinically suspected stable angina pectoris, no previous cardiac history, and normal left v

144 treatment of myocardial ischemia and angina pectoris not amenable to conventional percutaneous or su

145 treatment of myocardial ischemia and angina pectoris not amenable to conventional percutaneous or su

146 lf-reported QoL parameters related to angina pectoris, notably in terms of angina frequency and disea

147 ial infarction, but the prevalence of angina pectoris, of smoking, and of chest pain in the attack wa

148 860 patients underwent PCI for stable angina pectoris; of these, FFR guidance was used in 3,367.

149 Angina pectoris often results from ischemic episodes that excit

150 pants (HR = 1.17, 1.05-1.31) and with angina pectoris only in women (HR = 1.55, 1.03-2.33).

151 t failure OR myocardial infarction OR angina pectoris OR acute coronary syndrome OR coronary artery d

152 of presentation with either unstable angina pectoris or acute myocardial infarction.

153 ican region, older age, no history of angina pectoris or asthma, no use of hypoglycemic agent, more a

154 scularization, or with a diagnosis of angina pectoris or CHD defined by angiography.

155 ation of symptoms in patients who had angina pectoris or myocardial infarctions.

156 of 1473 patients with either unstable angina pectoris or non-Q-wave myocardial infarction (NQWMI) enr

157 ars or older, with stable or unstable angina pectoris or patients who had a myocardial infarction at

158 and less likely to have a history of angina pectoris (OR 0.58, 95% CI 0.34-0.99) compared with non-R

159 brillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association class s

160 oronary arteriography and 2) syncope, angina pectoris, or drug-related adverse event.

161 or adults with myocardial infarction, angina pectoris, or following coronary artery bypass graft, or

162 eart failure, coronary heart disease, angina pectoris, or myocardial infarction.

163 had stable angina pectoris, unstable angina pectoris, or non-ST-elevation myocardial infarction.

164 defined as new myocardial infarction, angina pectoris, or stroke, which developed between baseline an

165 We studied 124 chronic stable angina pectoris patients (84 men; mean age, 61+/-10 years) who

166 est in patients with suspected stable angina pectoris predicts the presence of coronary artery diseas

167 Candidates with angina pectoris, previous myocardial infarction, or congestive

168 tch-off hours in patients with stable angina pectoris receiving a beta-adrenergic blocking agent or c

169 performed in patients with refractory angina pectoris reduces ischemic wall motion abnormalities and

170 CHD, including myocardial infarction, angina pectoris, revascularization, and coronary death, occurre

171 rts of patients with suspected stable angina pectoris (SAP) (3033 patients; median 10.7 y follow-up;

172 nary angiography for suspected stable angina pectoris (SAP) (n = 4131) and an independent cohort of p

173 eferred for angiography due to stable angina pectoris (SAP) or acute coronary syndrome (ACS).

174 on AMI and unstable angina, or stable angina pectoris (SAP).

175 tion myocardial infarction and stable angina pectoris , similar patterns were found albeit less prono

176 t self-reported CHD (heart attack and angina pectoris), stroke, peripheral vascular disease, and diab

177 , all with significant improvement in angina pectoris that appears both rapid and sustained.

178 outcomes in patients with refractory angina pectoris treated with transmyocardial laser revasculariz

179 the best available therapy group) and angina pectoris (two [3%] of 74 in the ruxolitinib group vs non

180 nfarction (MI) (n = 205) and unstable angina pectoris (UAP) (n = 185).

181 l infarction (MI) (n =57) or unstable angina pectoris (UAP) (n =60) were consecutively recruited toge

182 Patients (n=141) with stable angina pectoris undergoing PCI had serial venous blood samples

183 Eligible patients had stable angina pectoris, unstable angina pectoris, or non-ST-elevation

184 es in patients presenting with stable angina pectoris, unstable angina pectoris,and ST-segment elevat

185 Overall improvement in angina pectoris was sustained at 1 year by at least one functio

186 Women with angina pectoris were less likely to undergo cardiac catheteriza

187 e duration of the episode of unstable angina pectoris were observed in 6 of 21 patients who died afte

188 going coronary angiography for stable angina pectoris were studied.

189 ng acute coronary syndrome and stable angina pectoris, were independent predictors of MACE.

190 catheter-based therapy for refractory angina pectoris when bypass surgery or angioplasty is not possi

191 an operative treatment for refractory angina pectoris when bypass surgery or percutaneous translumina

192 We observed a patient with unstable angina pectoris who developed foci of ischemic necroses in the

193 e observed in 10 patients with stable angina pectoris, with well-defined single vessel coronary arter

194 ated using CT images of patients with angina pectoris without known valvular disease (n = 95).

195 However, in the group with angina pectoris, women were considerably less likely to undergo

196 However, a diagnosis of stable angina pectoris yielded a differential association between PS a